Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03679949 · ClinicalTrials.gov registry record · Phase 1
Effects of Cannabis on Prescription Drug Abuse Liability and Analgesia
A Phase 1 study, sponsored by New York State Psychiatric Institute.
- Completed
- Registry status
- Phase 1
- Development phase
- 26
- Enrollment target
NCT03679949 is a Phase 1 study that has completed, run by New York State Psychiatric Institute. The registered enrollment target is 26 participants.
The verdict
NCT03679949, a Phase 1 study, has completed, sponsored by New York State Psychiatric Institute.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 26 participants
- Enrollment target
Study Summary
The purpose of this research is to assess the impact of cannabis on the analgesic and abuse-liability effects of a sub-threshold dose of a commonly used analgesic.
Interventions
- DRUG Placebo
- DRUG Oxycodone
- DRUG Cannabis (THC:CBD = ~ 1:0)
- DRUG Cannabis (THC:CBD = ~ 0:1)
- DRUG Cannabis (THC:CBD = ~ 1:1)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 26 participants |
| Start Date | 2019-04-01 |
| Est. Completion | 2022-12-06 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03679949
The ClinicalTrials.gov registry entry for NCT03679949 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 26 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is New York State Psychiatric Institute, which has 364 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which Placebo is the first listed.
NCT03679949 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03679949 about?
NCT03679949 is a clinical study titled "Effects of Cannabis on Prescription Drug Abuse Liability and Analgesia". The purpose of this research is to assess the impact of cannabis on the analgesic and abuse-liability effects of a sub-threshold dose of a commonly used analgesic.
What is the current status of trial NCT03679949?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 26 participants. The study started on 2019-04-01. Estimated completion is 2022-12-06.
What interventions are being tested in trial NCT03679949?
The interventions under investigation include: Placebo (DRUG), Oxycodone (DRUG), Cannabis (THC:CBD = ~ 1:0) (DRUG), Cannabis (THC:CBD = ~ 0:1) (DRUG), Cannabis (THC:CBD = ~ 1:1) (DRUG).
Who is sponsoring clinical trial NCT03679949?
This trial is sponsored by New York State Psychiatric Institute, which has 364 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.